Literature DB >> 21547498

Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia.

M E Visser1, N M Lammers, A J Nederveen, M van der Graaf, A Heerschap, M T Ackermans, H P Sauerwein, E S Stroes, M J Serlie.   

Abstract

AIMS/HYPOTHESIS: Hepatic steatosis is strongly associated with hepatic and whole-body insulin resistance. It has proved difficult to determine whether hepatic steatosis itself is a direct cause of insulin resistance. In patients with familial hypobetalipoproteinaemia (FHBL), hepatic steatosis is a direct consequence of impaired hepatic VLDL excretion, independently of metabolic derangements. Thus, patients with FHBL provide a unique opportunity to investigate the relation between increased liver fat and insulin sensitivity.
METHODS: We included seven male participants with FHBL and seven healthy matched controls. Intrahepatic triacylglycerol content and intramyocellular lipid content were measured using localised proton magnetic resonance spectroscopy (¹H-MRS). A two-step hyperinsulinaemic-euglycaemic clamp, using stable isotopes, was assessed to determine hepatic and peripheral insulin sensitivity.
RESULTS: ¹H-MRS showed moderate to severe hepatic steatosis in patients with FHBL. Basal endogenous glucose production (EGP) and glucose levels did not differ between the two groups, whereas insulin levels tended to be higher in patients compared with controls. Insulin-mediated suppression of EGP during lower dose insulin infusion and insulin-mediated peripheral glucose uptake during higher dose insulin infusion were comparable between FHBL participants and controls. Baseline fatty acids and lipolysis (glycerol turnover) at baseline and during the clamp did not differ between groups. CONCLUSIONS/
INTERPRETATION: In spite of moderate to severe hepatic steatosis, people with FHBL do not display a reduction in hepatic or peripheral insulin sensitivity compared with healthy matched controls. These results indicate that hepatic steatosis per se is not a causal factor leading to insulin resistance. TRIAL REGISTRATION: ISRCTN35161775.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21547498      PMCID: PMC3131507          DOI: 10.1007/s00125-011-2157-x

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  42 in total

1.  Standards of medical care in diabetes--2010.

Authors: 
Journal:  Diabetes Care       Date:  2010-01       Impact factor: 19.112

2.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.

Authors:  G Marchesini; M Brizi; G Bianchi; S Tomassetti; E Bugianesi; M Lenzi; A J McCullough; S Natale; G Forlani; N Melchionda
Journal:  Diabetes       Date:  2001-08       Impact factor: 9.461

3.  Assessment of hepatic insulin action in obese type 2 diabetic patients.

Authors:  P Staehr; O Hother-Nielsen; K Levin; J J Holst; H Beck-Nielsen
Journal:  Diabetes       Date:  2001-06       Impact factor: 9.461

Review 4.  Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.

Authors:  Hannele Yki-Järvinen
Journal:  Dig Dis       Date:  2010-05-07       Impact factor: 2.404

Review 5.  Lipid-induced insulin resistance: unravelling the mechanism.

Authors:  Varman T Samuel; Kitt Falk Petersen; Gerald I Shulman
Journal:  Lancet       Date:  2010-06-26       Impact factor: 79.321

6.  Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia.

Authors:  Anastassia Amaro; Elisa Fabbrini; Marleen Kars; Pin Yue; Kenneth Schechtman; Gustav Schonfeld; Samuel Klein
Journal:  Gastroenterology       Date:  2010-03-18       Impact factor: 22.682

7.  The quantification of gluconeogenesis in healthy men by (2)H2O and [2-(13)C]glycerol yields different results: rates of gluconeogenesis in healthy men measured with (2)H2O are higher than those measured with [2-(13)C]glycerol.

Authors:  M T Ackermans; A M Pereira Arias; P H Bisschop; E Endert; H P Sauerwein; J A Romijn
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

8.  Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men.

Authors:  Anneli Seppälä-Lindroos; Satu Vehkavaara; Anna-Maija Häkkinen; Takashi Goto; Jukka Westerbacka; Anssi Sovijärvi; Juha Halavaara; Hannele Yki-Järvinen
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

9.  Java-based graphical user interface for the MRUI quantitation package.

Authors:  A Naressi; C Couturier; J M Devos; M Janssen; C Mangeat; R de Beer; D Graveron-Demilly
Journal:  MAGMA       Date:  2001-05       Impact factor: 2.533

10.  Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene.

Authors:  Konstantinos Kantartzis; Andreas Peter; Fausto Machicao; Jürgen Machann; Silvia Wagner; Ingmar Königsrainer; Alfred Königsrainer; Fritz Schick; Andreas Fritsche; Hans-Ulrich Häring; Norbert Stefan
Journal:  Diabetes       Date:  2009-08-03       Impact factor: 9.461

View more
  28 in total

1.  Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome.

Authors:  Luca Miele; Giovanni Gasbarrini; Valentina Giorgio; Antonio Gasbarrini; Antonio Grieco
Journal:  Intern Emerg Med       Date:  2015-11-24       Impact factor: 3.397

2.  Beneficial effects of a red wine polyphenol extract on high-fat diet-induced metabolic syndrome in rats.

Authors:  Nathalie Auberval; Stéphanie Dal; Elisa Maillard; William Bietiger; Claude Peronet; Michel Pinget; Valérie Schini-Kerth; Séverine Sigrist
Journal:  Eur J Nutr       Date:  2016-02-25       Impact factor: 5.614

Review 3.  Hypobetalipoproteinemia and abetalipoproteinemia.

Authors:  Francine K Welty
Journal:  Curr Opin Lipidol       Date:  2014-06       Impact factor: 4.776

4.  Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects.

Authors:  Faidon Magkos; Xiong Su; David Bradley; Elisa Fabbrini; Caterina Conte; J Christopher Eagon; J Esteban Varela; Elizabeth M Brunt; Bruce W Patterson; Samuel Klein
Journal:  Gastroenterology       Date:  2012-03-13       Impact factor: 22.682

Review 5.  Dissociating fatty liver and diabetes.

Authors:  Zheng Sun; Mitchell A Lazar
Journal:  Trends Endocrinol Metab       Date:  2012-10-05       Impact factor: 12.015

Review 6.  Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis.

Authors:  Dirk J Blom; Frederick J Raal; Raul D Santos; A David Marais
Journal:  Curr Atheroscler Rep       Date:  2019-11-19       Impact factor: 5.113

7.  Meal timing effects on insulin sensitivity and intrahepatic triglycerides during weight loss.

Authors:  R I Versteeg; M T Ackermans; A J Nederveen; E Fliers; M J Serlie; S E la Fleur
Journal:  Int J Obes (Lond)       Date:  2017-08-16       Impact factor: 5.095

Review 8.  Update on primary hypobetalipoproteinemia.

Authors:  Amanda J Hooper; John R Burnett
Journal:  Curr Atheroscler Rep       Date:  2014-07       Impact factor: 5.113

9.  Ectopic fat deposition in prediabetic overweight and obese minority adolescents.

Authors:  Claudia M Toledo-Corral; Tanya L Alderete; Houchun H Hu; Krishna Nayak; Sherryl Esplana; Ting Liu; Michael I Goran; Marc J Weigensberg
Journal:  J Clin Endocrinol Metab       Date:  2013-02-05       Impact factor: 5.958

10.  Hepatic mitochondrial oxidative phosphorylation is normal in obese patients with and without type 2 diabetes.

Authors:  Michael Taulo Lund; Marianne Kristensen; Merethe Hansen; Louise Tveskov; Andrea Karen Floyd; Mikael Støckel; Ben Vainer; Steen Seier Poulsen; Jørn Wulff Helge; Clara Prats; Flemming Dela
Journal:  J Physiol       Date:  2016-08-01       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.